Blood pressure drug shows promise against resistant ovarian cancer
NCT ID NCT06815497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with ovarian cancer that no longer responds to platinum-based treatments. About 33 adults with this type of cancer will receive the combination, and researchers will measure how long the cancer stays under control compared to past patients. The goal is to find a better way to manage the disease when standard options have failed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Dartmouth Hitchcock
RECRUITINGLebanon, New Hampshire, 03756, United States
-
Dartmouth-Hitchcock Manchester
RECRUITINGManchester, New Hampshire, 03104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?